ICCC IMMUCELL CORP /DE/
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 811641 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.6%
TTM net income YoY-19.1%
TTM EPS YoY-32.1%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—
Margins
Gross margin40.8%
Operating margin14.5%
Net margin5.7%
FCF margin16.3%
EBITDA margin21.0%
Returns
ROE6.0%
ROA4.2%
ROIC (approx.)13.8%
Asset turnover0.73x
Leverage & solvency
Liabilities / assets31.7%
Debt / equity0.24x
Current ratio4.61x
Interest coverage12.19x
Cash quality & payout
Operating cash flow / net income4.17x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue7.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.04M | $7.19M | $10.36M | $7.63M | $5.51M | $6.44M | $8.07M | $7.75M |
| Cost of revenue | $4.48M | $4.75M | $5.70M | $4.72M | $3.14M | $3.63M | $4.71M | $4.92M |
| Gross profit | $3.56M | $2.44M | $4.66M | $2.91M | $2.36M | $2.82M | $3.35M | $2.83M |
| R&D expense | $176,771 | $119,652 | $317,688 | $758,864 | $694,311 | $831,858 | $756,847 | $819,393 |
| SG&A expense | $1.29M | $1.27M | $1.14M | $1.13M | $729,421 | $720,418 | $622,843 | $554,711 |
| Operating income | $957,770 | $1.93M | $1.97M | -$57,956 | $20,075 | $569,562 | $1.12M | $621,395 |
| Interest expense | $92,527 | $95,667 | $99,675 | $106,145 | $134,516 | $124,795 | $127,928 | $136,196 |
| Pretax income | $935,275 | $1.88M | $1.95M | -$2.85M | -$135,292 | $503,784 | $1.45M | $520,591 |
| Income tax | -$17,235 | $45,950 | $12,522 | $3,306 | $4,456 | $1,904 | $1,904 | $6,036 |
| Net income | $952,510 | $1.83M | $1.94M | -$2.85M | -$139,748 | $501,880 | $1.45M | $514,555 |
| EBITDA | $1.42M | $2.41M | $2.50M | $651,516 | $728,742 | $1.25M | $1.80M | $1.31M |
| EPS (basic) | 0.10 | 0.20 | 0.21 | — | -0.02 | 0.06 | 0.16 | — |
| EPS (diluted) | 0.10 | 0.20 | 0.21 | — | -0.02 | 0.06 | 0.16 | — |
| Weighted avg. shares (diluted) | 9.30M | 9.19M | 9.05M | — | 9.05M | 9.03M | 8.98M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.91M | $8.86M | $6.81M | $3.81M | $3.89M | $6.00M | $4.60M | $3.76M |
| Receivables | $3.37M | $2.90M | $2.69M | $3.42M | $2.55M | $2.38M | $3.35M | $3.77M |
| Inventory | $9.86M | $9.08M | $8.67M | $9.27M | $9.80M | $8.29M | $7.36M | $7.11M |
| Current assets | $21.58M | $21.08M | $18.86M | $16.94M | $16.83M | $17.14M | $15.92M | $15.04M |
| PP&E, net | $21.92M | $21.03M | $20.78M | $21.07M | $24.34M | $24.88M | $25.02M | $25.35M |
| Goodwill | $95,557 | $95,557 | $95,557 | $95,557 | $95,557 | $95,557 | $95,557 | $95,557 |
| Intangibles | — | — | — | $0 | $4,776 | $9,552 | $14,328 | $19,104 |
| Total assets | $47.96M | $46.63M | $44.11M | $42.53M | $42.53M | $42.53M | $45.62M | $45.10M |
| Current liabilities | $4.68M | $4.44M | $3.91M | $3.98M | $4.00M | $4.45M | $3.87M | $4.41M |
| Short-term debt | $1.38M | $1.51M | $1.63M | $1.61M | $1.59M | $1.54M | $1.52M | $1.50M |
| Long-term debt | $6.52M | $6.80M | $7.07M | $7.49M | $7.90M | $8.26M | $8.65M | $9.04M |
| Total debt | $7.90M | $8.30M | $8.70M | $9.10M | $9.49M | $9.80M | $10.17M | $10.54M |
| Total liabilities | $15.18M | $15.26M | $14.97M | $15.48M | $15.93M | $16.85M | $16.63M | $17.58M |
| Shareholders' equity | $32.77M | $31.37M | $29.14M | $27.06M | $29.80M | $29.87M | $28.99M | $27.52M |
| Net debt | -$15,557 | -$557,319 | $1.89M | $5.29M | $5.60M | $3.80M | $5.57M | $6.78M |
| Shares outstanding | 9.09M | 9.08M | 9.05M | 9.05M | 9.05M | 9.05M | 8.98M | 8.98M |
| Cash flow statement | ||||||||
| Operating cash flow | $755,906 | $3.02M | $3.57M | $482,541 | -$1.18M | $1.60M | $1.57M | -$3,051 |
| Capital expenditure | $1.35M | $733,939 | $177,230 | $172,306 | $593,924 | $155,159 | $329,050 | $196,216 |
| Free cash flow | -$589,355 | $2.29M | $3.40M | $310,235 | -$1.78M | $1.45M | $1.24M | -$199,267 |
| Investing cash flow | -$1.35M | -$733,939 | -$167,230 | -$167,306 | -$592,024 | -$125,927 | -$329,050 | -$196,216 |
| Financing cash flow | -$356,444 | -$237,564 | -$399,995 | -$394,602 | -$337,689 | -$76,448 | -$403,647 | $148,866 |
| Depreciation & amortization | $459,357 | $470,621 | $531,452 | $709,472 | $708,667 | $679,037 | $686,773 | $684,655 |
| Stock-based compensation | $396,457 | $239,867 | $137,949 | $103,781 | $73,161 | $66,714 | $52,215 | $68,863 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.